- Home
- PRME vs ABUS Comparison
PRME vs ABUS Comparison
Compare PRME & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- ABUS
- Stock Information
- Founded
- PRME 2019
- ABUS N/A
- Country
- PRME United States
- ABUS United States
- Employees
- PRME N/A
- ABUS N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- ABUS Health Care
- Exchange
- PRME Nasdaq
- ABUS Nasdaq
- Market Cap
- PRME 424.9M
- ABUS 629.1M
- IPO Year
- PRME 2022
- ABUS N/A
- Fundamental
- Price
- PRME $2.70
- ABUS $3.18
- Analyst Decision
- PRME Strong Buy
- ABUS Strong Buy
- Analyst Count
- PRME 9
- ABUS 4
- Target Price
- PRME $13.13
- ABUS $5.50
- AVG Volume (30 Days)
- PRME 1.1M
- ABUS 898.2K
- Earning Date
- PRME 02-28-2025
- ABUS 02-27-2025
- Dividend Yield
- PRME N/A
- ABUS N/A
- EPS Growth
- PRME N/A
- ABUS N/A
- EPS
- PRME N/A
- ABUS N/A
- Revenue
- PRME $800,000.00
- ABUS $6,742,000.00
- Revenue This Year
- PRME N/A
- ABUS N/A
- Revenue Next Year
- PRME $426.55
- ABUS N/A
- P/E Ratio
- PRME N/A
- ABUS N/A
- Revenue Growth
- PRME N/A
- ABUS N/A
- 52 Week Low
- PRME $2.56
- ABUS $2.21
- 52 Week High
- PRME $9.77
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- PRME 39.60
- ABUS 40.45
- Support Level
- PRME $2.74
- ABUS $3.13
- Resistance Level
- PRME $3.59
- ABUS $3.54
- Average True Range (ATR)
- PRME 0.23
- ABUS 0.14
- MACD
- PRME 0.00
- ABUS 0.01
- Stochastic Oscillator
- PRME 7.29
- ABUS 16.28
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.